Catheter Precision, Inc. Announces Allowance of Key Intellectual Property
Rhea-AI Summary
Catheter Precision (NYSE American: VTAK) announced allowance and issuance of multiple patents covering its heart failure and vascular closure technologies. The heart failure portfolio gained six new US patents and two international patents, while vascular closure added one issued US patent and two allowed US applications.
The three vascular closure patents, including US patent no. 12,622,686 dated May 12, 2026, pertain to the LockeT product marketed in the US and Europe. According to the company, these additions expand a library of over fifty patents and support ongoing discussions about the potential sale of these two technologies.
Positive
- Eight new heart failure patents, including six US and two international
- Three new US vascular closure patents tied to marketed LockeT product
- Patent portfolio now exceeds fifty patents across key product areas
- New IP may support value in ongoing sale discussions for two technologies
Negative
- No financial terms or valuation disclosed for potential technology sale
- Discussions on selling the two technologies remain pending, with no agreement announced
News Market Reaction – VTAK
In the Jun 22 session, VTAK gained 3.54%, reflecting a moderate positive market reaction. Argus tracked a peak move of +78.9% during that session. Our momentum scanner triggered 26 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 186.4x the daily average, suggesting very strong buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 11 | Aviation partnership | Positive | -2.7% | Flyte joined Vaunt’s operator network to tap its private aviation member base. |
| Jun 09 | World Cup strategy | Positive | -3.4% | Flyte outlined plans to capture 2026 World Cup regional travel demand. |
| Jun 08 | Strategic investment | Positive | +1.0% | Flyte acquired Volato shares, becoming a major shareholder to support collaboration. |
| Jun 08 | Volato financing | Positive | +1.0% | Volato secured a strategic equity investment led by Catheter Precision and others. |
| Jun 02 | Event-driven flights | Positive | +4.3% | Flyte deployed its fleet for high-frequency Belmont Stakes travel demand. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent VTAK news often reads positively but has produced mixed price reactions, with several sell-offs after seemingly constructive operational updates.
Key Terms
heart failure medical
vascular closure medical
intellectual property regulatory
patent applications regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Eight New Patents Issued on Heart Failure Technology
Three New Patents Granted on Vascular Closure Technology
FORT MILL, S.C., June 22, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK: NYSE/American), today announced the allowance of a number of patents issued over the last few months, including both methods and devices, covering key areas of its technology for both the Company’s heart failure technologies and the vascular closure technologies. The heart failure patents include six patents issued in the US and two issued in international markets. The vascular closure patents include one issued patent and two allowed patent applications soon to be issued and are all US patents. These three vascular closure patents (including the newest issue of US patent no. 12,622,686, dated May 12, 2026) pertain to the LockeT product which the Company currently markets in the US and Europe.
David Jenkins, CEO of Catheter Precision, Inc., commented, “We are pleased to see that work over several years is validated through the issuance of new intellectual property. This joins a VTAK patent library of over fifty patents in important product areas. Given the fact that we are now in discussions regarding the sale of these two technologies, these new patents certainly fortify the offerings and hopefully enhance the discussions.”
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
About Flyte
Flyte is a technology-enabled Regional Air Mobility Company operating a growing fleet of Cirrus Vision Jets. Focused on high frequency, short haul markets, Flyte provides a faster, safer, and more efficient alternative to traditional private charter travel.
Flight operations are conducted through Flyte’s wholly owned subsidiary, Ponderosa Air, LLC, an FAA certified Part 135 air carrier. With certified aircraft, active revenue generating operations, and scalable fleet expansion underway, Flyte is building disciplined, asset backed aviation infrastructure designed to serve underserved regional markets.
For more information, visit www.flyte.travel
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.
About Cardionomix
Cardionomix is a medical device company owned by Catheter Precision focused on developing a new therapy based upon novel technology for the treatment of acute decompensated heart failure, or ADHF, for which over 1 million Americans are hospitalized annually.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
# # #
